November 8 - 12, 2008
New Orleans, Louisiana, USA
Data from the phase II ATLAS ACS TIMI 46 study of Xarelto® (rivaroxaban) were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.
with
Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
Background Information | |
|---|---|
About Xarelto® |  PDF / 477 KB  collect081110_About_Xarelto.pdf About Xarelto |
About Xarelto®Clinical Studies |
|
About the ATLAS ACS TIMI Trial Program |
|
About the RECORD Studies |
|
Understanding Acute Coronary Syndrome |
|
The History of Anticoagulants |
|
Understanding Venous Blood Clots |
|
Glossary |
|